Table 4 The comparison of disease severity and clinical outcome patient with and without selenium administration.
From: Impact of selenium status and supplementation on outcomes in critically ill patients
Total sample n = 40 | Supplement Se (+) n = 23 | Supplement Se (−) n = 17 | P value | |
|---|---|---|---|---|
Disease severity | ||||
APACHE II | 24.7 ± 9.3 | 24.5 ± 8.5 | 25.1 ± 10.5 | 0.956 |
SOFA | 8.6 ± 4.3 | 8.0 ± 3.9 | 9.3 ± 4.9 | 0.483 |
TISS | 31.4 ± 9.4 | 31.7 ± 8.4 | 30.9 ± 10.8 | 0.602 |
Glasgow coma scale | 8.9 ± 4.7 | 9.0 ± 4.8 | 8.8 ± 4.6 | 0.923 |
P/F ratio < 300 | 18(45%) | 8(34.8%) | 10(58.8%) | 0.131 |
Mechanical ventilation (%) | 29(72.5%) | 16(69.6%) | 13(76.5%) | 0.730 |
Cause of ICU admission | ||||
Sepsis | 29(72.5%) | 16(69.6%) | 13(76.5%) | 0.730 |
Septic shock | 22(55%) | 14(60.9%) | 8(47.1%) | 0.385 |
Gastrointestinal bleeding | 1(2.5%) | 1(4.3%) | 0(0%) | 1.000 |
Pneumonia | 20(50%) | 11(47.8%) | 9(52.9%) | 0.749 |
Outcome | ||||
ICU survival | 32(80%) | 21(91.3%) | 11(64.7%) | 0.053 |
ICU length | 12.5 ± 10.1 | 13.8 ± 11.4 | 10.8 ± 8.0 | 0.365 |
Hospital survival | 22(55%) | 13 (56.5%) | 9(52.9%) | 0.822 |
Hospital length | 31.4 ± 24.9 | 31.3 ± 22.2 | 31.6 ± 29.0 | 0.593 |
